AnGes, Inc. Logo

AnGes, Inc.

Biopharmaceutical firm developing gene-based and nucleotide-based medicines.

4563 | T

Overview

Corporate Details

ISIN(s):
JP3127700007
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号

Description

AnGes, Inc. is a biopharmaceutical company specializing in the research and development of gene-based and nucleotide-based medicines. The company's core focus is its Hepatocyte Growth Factor (HGF) gene therapy product, designed to treat ischemic diseases by regenerating blood vessels. This product was the first gene therapy medicine to receive marketing approval in Japan. AnGes leverages its expertise in plasmid DNA technology across its development pipeline, which also includes an NFkB decoy oligonucleotide and DNA vaccines. The company is dedicated to developing novel treatments for various conditions, including rare diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-07 07:30
有価証券届出書(参照方式)
Japanese ZIP 244.5 KB
2025-08-13 06:50
確認書
Japanese ZIP 8.9 KB
2025-08-13 04:19
半期報告書-第27期(2025/01/01-2025/12/31)
Japanese ZIP 488.0 KB
2025-03-31 04:52
臨時報告書
Japanese ZIP 25.5 KB
2025-03-31 03:22
内部統制報告書-第26期(2024/01/01-2024/12/31)
Japanese ZIP 23.7 KB
2025-03-31 03:18
確認書
Japanese ZIP 8.9 KB
2025-03-31 03:17
有価証券報告書-第26期(2024/01/01-2024/12/31)
Japanese ZIP 1.5 MB
2024-09-03 06:05
訂正有価証券届出書(参照方式)
Japanese ZIP 203.2 KB
2024-08-30 09:06
有価証券届出書(参照方式)
Japanese ZIP 381.2 KB
2024-08-14 02:28
確認書
Japanese ZIP 8.9 KB
2024-08-14 02:27
半期報告書-第26期(2024/01/01-2024/12/31)
Japanese ZIP 725.7 KB
2024-05-14 02:27
確認書
Japanese ZIP 8.9 KB
2024-05-14 02:25
四半期報告書-第26期第1四半期(2024/01/01-2024/03/31)
Japanese ZIP 457.7 KB
2024-03-29 01:45
臨時報告書
Japanese ZIP 24.0 KB
2024-03-29 01:43
内部統制報告書-第25期(2023/01/01-2023/12/31)
Japanese ZIP 23.6 KB

Automate Your Workflow. Get a real-time feed of all AnGes, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AnGes, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AnGes, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.